CY1124552T1 - Θειενοπυριδινες και βενζοθειοφαινια χρησιμα ως αναστολεις irak4 - Google Patents

Θειενοπυριδινες και βενζοθειοφαινια χρησιμα ως αναστολεις irak4

Info

Publication number
CY1124552T1
CY1124552T1 CY20211100874T CY211100874T CY1124552T1 CY 1124552 T1 CY1124552 T1 CY 1124552T1 CY 20211100874 T CY20211100874 T CY 20211100874T CY 211100874 T CY211100874 T CY 211100874T CY 1124552 T1 CY1124552 T1 CY 1124552T1
Authority
CY
Cyprus
Prior art keywords
benzothiophenies
thienopyridines
compounds
irak4 inhibitors
treatment
Prior art date
Application number
CY20211100874T
Other languages
English (en)
Inventor
Saleem Ahmad
Lidet A. Negash
John Hynes
Ling Li
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of CY1124552T1 publication Critical patent/CY1124552T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Αποκαλυπτόμενες είναι ενώσεις του Τύπου (Ι) ή άλας ή προφάρμακο αυτών, όπου: Χ είναι CR4 ή Ν· Υ είναι CR5 ή Ν· υπό την προϋπόθεση ότι μόνο μία των Χ και Υ είναι Ν· (R1) είναι ή: όπου R1, R1a, R1b, R1c, R2, και R3 ορίζονται στο παρόν. Επίσης αποκαλυπτόμενες είναι μέθοδοι χρήσης τέτοιων ενώσεων ως ρυθμιστών IRAK4, και φαρμακευτικές συνθέσεις που περιλαμβάνουν τέτοιες ενώσεις. Αυτές οι ενώσεις είναι χρήσιμες στη θεραπεία, αποτροπή, ή επιβράδυνση φλενμονωδών και αυτοάνοσων ασθενειών, ή στη θεραπεία καρκίνου.
CY20211100874T 2017-05-11 2021-10-07 Θειενοπυριδινες και βενζοθειοφαινια χρησιμα ως αναστολεις irak4 CY1124552T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762504956P 2017-05-11 2017-05-11
PCT/US2018/031945 WO2018209012A1 (en) 2017-05-11 2018-05-10 Thienopyridines and benzothiophenes useful as irak4 inhibitors

Publications (1)

Publication Number Publication Date
CY1124552T1 true CY1124552T1 (el) 2022-07-22

Family

ID=62245511

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100874T CY1124552T1 (el) 2017-05-11 2021-10-07 Θειενοπυριδινες και βενζοθειοφαινια χρησιμα ως αναστολεις irak4

Country Status (27)

Country Link
US (1) US10829496B2 (el)
EP (1) EP3621960B1 (el)
JP (1) JP7154229B2 (el)
KR (1) KR102604900B1 (el)
CN (1) CN110612298B (el)
AR (1) AR111689A1 (el)
AU (1) AU2018265130B2 (el)
BR (1) BR112019023290A2 (el)
CA (1) CA3062602A1 (el)
CL (1) CL2019003198A1 (el)
CO (1) CO2019012494A2 (el)
CY (1) CY1124552T1 (el)
DK (1) DK3621960T3 (el)
EA (1) EA039189B1 (el)
ES (1) ES2889926T3 (el)
HR (1) HRP20211583T1 (el)
HU (1) HUE056493T2 (el)
IL (1) IL270494B (el)
LT (1) LT3621960T (el)
MX (1) MX2019012929A (el)
PE (1) PE20191817A1 (el)
PL (1) PL3621960T3 (el)
PT (1) PT3621960T (el)
RS (1) RS62430B1 (el)
SI (1) SI3621960T1 (el)
TW (1) TW201900640A (el)
WO (1) WO2018209012A1 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018338314A1 (en) 2017-09-22 2020-04-09 Kymera Therapeutics, Inc Protein degraders and uses thereof
EP3684366A4 (en) 2017-09-22 2021-09-08 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES OF THE LATEST
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
JP2021508703A (ja) 2017-12-26 2021-03-11 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
EP3737675A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. CRBN LIGANDS AND THEIR USES
EP3817748A4 (en) 2018-07-06 2022-08-24 Kymera Therapeutics, Inc. TRICYCLIC CRBN LIGANDS AND USES THEREOF
SG11202105424PA (en) 2018-11-30 2021-06-29 Kymera Therapeutics Inc Irak degraders and uses thereof
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
JP2022541819A (ja) * 2019-07-23 2022-09-27 ブリストル－マイヤーズ スクイブ カンパニー Ｉｒａｋ４阻害剤として有用なチエノピリジニルおよびチアゾロピリジニル化合物
IL293917A (en) 2019-12-17 2022-08-01 Kymera Therapeutics Inc Iraq joints and their uses
EP4076524A4 (en) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
CN111285844B (zh) * 2020-02-24 2022-08-12 河南师范大学 具有生物活性的苯并噻吩取代酰胺类化合物及其合成方法和应用
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8627698D0 (en) * 1986-11-20 1986-12-17 Boots Co Plc Therapeutic agents
ATE432929T1 (de) 2001-06-15 2009-06-15 Vertex Pharma 5-(2-aminopyrimidin-4-yl)benzisoxazole als proteinkinasehemmer
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
GB0211019D0 (en) 2002-05-14 2002-06-26 Syngenta Ltd Novel compounds
US7449456B2 (en) 2002-06-28 2008-11-11 Astellas Pharma, Inc. Diaminopyrimidinecarboxamide derivative
BRPI0406809A (pt) 2003-01-17 2005-12-27 Warner Lambert Co Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
CA2531401A1 (en) 2003-07-10 2005-01-27 Neurogen Corporation Substituted heterocyclic diarylamine analogues
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
US20060281778A1 (en) 2005-03-09 2006-12-14 Schering Corporation Compounds for inhibiting KSP Kinesin activity
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
AR059246A1 (es) 2006-01-30 2008-03-19 Array Biopharma Inc Compuestos heterobiciclicos de tiofeno y metodos de uso
AU2008258508A1 (en) 2007-06-08 2008-12-11 Bayer Cropscience Ag Fungicide heterocyclyl-pyrimidinyl-amino derivatives
WO2009046416A1 (en) 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
JP5254693B2 (ja) 2008-07-30 2013-08-07 三菱重工業株式会社 Ｎｉ基合金用溶接材料
EP2361902A4 (en) 2008-11-21 2012-04-25 Astellas Pharma Inc 4,6-DIAMINONICOTINSÄUREAMIDVERBINDUNG
EA021367B1 (ru) 2008-11-28 2015-06-30 Кова Компани, Лтд. Производное пиридин-3-карбоксамида
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
CN102458402B (zh) 2009-06-12 2013-10-02 百时美施贵宝公司 用作激酶调节剂的烟酰胺化合物
SG178963A1 (en) 2009-09-03 2012-04-27 Allergan Inc Compounds as tyrosine kinase modulators
JP5770198B2 (ja) 2009-10-30 2015-08-26 ヤンセン ファーマシューティカ エヌ．ベー． オピオイド受容体調節因子としてのフェノキシ置換ピリミジン
KR20120130104A (ko) 2010-02-01 2012-11-28 닛뽕 케미파 가부시키가이샤 Ｇｐｒ119 작동약
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
CN103619854A (zh) 2011-04-29 2014-03-05 西奈山伊坎医学院 激酶抑制剂
WO2013106612A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
CN104254533B (zh) 2012-01-13 2017-09-08 百时美施贵宝公司 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物
ES2630705T3 (es) 2012-01-13 2017-08-23 Bristol-Myers Squibb Company Compuestos de piridilo sustituidos con triazolilo útiles como inhibidores de cinasas
KR102233252B1 (ko) 2012-11-08 2021-03-26 브리스톨-마이어스 스큅 컴퍼니 ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물
PE20150953A1 (es) 2012-11-08 2015-06-20 Bristol Myers Squibb Co Compuestos de piridilo sustituidos con heteroarilo utiles como moduladores de cinasa
JP6215338B2 (ja) 2012-11-08 2017-10-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ キナーゼモジュレーターとして有用な二環式ヘテロ環置換ピリジル化合物
TWI582077B (zh) 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
EA032559B1 (ru) 2014-04-04 2019-06-28 Пфайзер Инк. Бициклические аннелированные гетероарильные или арильные соединения и их применение в качестве ингибиторов irak4
EP3268003B1 (en) * 2015-03-12 2020-07-29 Merck Sharp & Dohme Corp. Thienopyrazine inhibitors of irak4 activity
US10155765B2 (en) * 2015-03-12 2018-12-18 Merck Sharp & Dohme Corp. Carboxamide inhibitors of IRAK4 activity
EP3313844B1 (en) 2015-06-24 2020-08-26 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
CN107849039B (zh) 2015-06-24 2020-07-03 百时美施贵宝公司 经杂芳基取代的氨基吡啶化合物
WO2017033093A1 (en) 2015-08-27 2017-03-02 Pfizer Inc. Bicyclic-fused heteroaryl or aryl compounds as irak4 modulators

Also Published As

Publication number Publication date
US20200062777A1 (en) 2020-02-27
HRP20211583T1 (hr) 2022-01-07
ES2889926T3 (es) 2022-01-14
IL270494B (en) 2022-04-01
KR20200004871A (ko) 2020-01-14
HUE056493T2 (hu) 2022-02-28
BR112019023290A2 (pt) 2020-06-16
KR102604900B1 (ko) 2023-11-21
PT3621960T (pt) 2021-09-16
US10829496B2 (en) 2020-11-10
PE20191817A1 (es) 2019-12-27
CL2019003198A1 (es) 2020-03-20
AU2018265130A1 (en) 2020-01-02
DK3621960T3 (da) 2021-09-27
EA201992674A1 (ru) 2020-04-06
WO2018209012A1 (en) 2018-11-15
EA039189B1 (ru) 2021-12-15
RS62430B1 (sr) 2021-11-30
EP3621960A1 (en) 2020-03-18
LT3621960T (lt) 2021-10-11
JP7154229B2 (ja) 2022-10-17
SI3621960T1 (sl) 2021-11-30
AU2018265130B2 (en) 2022-03-24
CN110612298B (zh) 2023-05-05
JP2020519596A (ja) 2020-07-02
AR111689A1 (es) 2019-08-07
CA3062602A1 (en) 2018-11-15
PL3621960T3 (pl) 2021-11-08
CN110612298A (zh) 2019-12-24
EP3621960B1 (en) 2021-08-04
TW201900640A (zh) 2019-01-01
CO2019012494A2 (es) 2020-01-17
MX2019012929A (es) 2020-01-14

Similar Documents

Publication Publication Date Title
CY1124552T1 (el) Θειενοπυριδινες και βενζοθειοφαινια χρησιμα ως αναστολεις irak4
CY1125214T1 (el) Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος
CY1120834T1 (el) Δικυκλικες αζωτουχες ενωσεις ως αγωνιστες μουσκαρινικων υποδοχεων μ1
CY1124187T1 (el) Ετεροκυκλικα αμιδια ως αναστολεις κινασης
CY1124496T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
CY1122821T1 (el) Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2
CY1124055T1 (el) Ετεροκυκλικες ενωσεις ως ανοσοδιαμορφωτες
CY1123645T1 (el) Δικυκλικα παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα
CY1120361T1 (el) Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido)
CY1123223T1 (el) Παραγωγα πυραζολιου ως αναστολεις καλλικρεϊνης πλασματος
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
CO2018008761A2 (es) Derivados de maitansinoide, conjugados de los mismos métodos de uso
MA51290A (fr) Nouvelles pyridopyrimidinones à substitution benzylamino et dérivés à utiliser en tant qu'inhibiteurs de sos1
CY1122560T1 (el) Νεα παραγωγα αμμωνιου, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουναυτα
CY1119585T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
CY1124173T1 (el) Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες
CY1124620T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
CY1124798T1 (el) Υποκατεστημενα παραγωγα καρβονουκλεοζιδιων χρησιμα ως παραγοντες κατα των καρκινων
CY1121677T1 (el) Ενωσεις διμεθυλοβενζοϊκου οξεος
CY1123349T1 (el) Ενωσεις 6-ετεροκυκλυλ-4-μορφολιν-4-υλπυρiδιν-2-οnhς χρησιμες για τη θεραπεια καρκινου και διαβητη
CY1123374T1 (el) Αμιδια ετεροαρυλιου ως αναστολεις της συσσωματωσης πρωτεϊνων
PE20210452A1 (es) Inhibidores de la arginasa
CO2019002517A2 (es) Inhibidores de dopamina–β–hidroxilasa
CY1123582T1 (el) Προφαρμακα των αναστολεων αντιστροφης μεταγραφασης hiv